# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001140361-26-003219
**Filing Date:** 2026-2
**Character Count:** 3401
**Document Hash:** ccc8a849e4f29b6be51ad9eddef99c49
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-003219.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001140361-26-003219

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**EFFECTIVENESS DATE**: 20260202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37467
- **FILM NUMBER:** 26587817

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 15
**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number <u> 001-37467 </u>

ASTRIA THERAPEUTICS, INC.

------

(Exact name of registrant as specified in its charter)

**22 Boston Wharf Road**

<br> #### 10<sup>th</sup> Floor

#### Boston, Massachusetts 02210
(617) 349-1971

(Address, including zip code, and telephone number, including area code,<br>

of registrant's principal executive offices)

#### Common Stock, par value $0.001 per share

------

(Title of each class of securities covered by this Form)

#### None

------

(Titles of all other classes of securities for which a duty to file reports<br>

under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One\*

\*Effective as of January 23, 2026, pursuant to the Agreement and Plan of Merger, dated as of October 14, 2025, by and among BioCryst Pharmaceuticals, Inc., a Delaware corporation ("BioCryst"), Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("Merger Sub"), and Astria Therapeutics, Inc. ("Astria"), Merger Sub was merged with and into Astria, with Astria surviving as a wholly owned subsidiary of BioCryst.

------

Pursuant to the requirements of the Securities Exchange Act of 1934, Astria Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **Astria Therapeutics, Inc.** | **Astria Therapeutics, Inc.** |
| Date: February 2, 2026 | By: | /s/ Alane Barnes |
|  |  | Alane Barnes |
|  |  | Secretary |

---

2<br>

------